Compare CarMax, Inc (KMX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs 10X Genomics Inc — how do they compare? CarMax, Inc trades at $55.91 (market cap $7.93B), while 10X Genomics Inc trades at $47.48 (market cap $5.48B). The key difference: CarMax, Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| KMX | TXG | |
|---|---|---|
Market Cap | $7.93B | $5.48B |
Sector | Consumer Cyclical | Health |
52-Week High | $63.53 | $45.80 |
52-Week Low | $30.88 | $11.34 |
Enterprise Value | $26.44B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $57.61, up 0.49% on the day, with a bullish technical outlook supported by moving averages and a strong ADX signal. Recent Q1 2026 earnings beat expectations, driven by cost control and revenue growth, though net income margins remain thin at 0.84%. The company's four-pillar strategy focuses on volume, digital sales, and efficiency, with positive analyst coverage highlighting value and momentum potential.
The stock's upside is supported by operational improvements and insider buying, but risks include high debt levels, margin pressure, and a pending legal investigation. Analyst consensus is cautious with a $48.91 price target below the current price, suggesting limited near-term upside amid execution risks.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
